Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.57 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.40 |
| ▸ | TLR4 | O00206 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30508248 | 0.99 | TLR8 (0.56) | TLR8TLR7TLR9TLR4IRAK4 | |
| Hydrochloric Acid SCHEMBL28215605 | 0.99 | TLR8 (0.56) | TLR8TLR7TLR9TLR4IRAK4 | |
| SCHEMBL30508196 | 0.92 | TLR8 (0.49) | TLR8TLR7TLR9TLR4IRAK4 | |
| SCHEMBL30508251 | 0.92 | TLR8 (0.49) | TLR8TLR7TLR9TLR4IRAK4 | |
| Hydrochloric Acid SCHEMBL30508246 | 0.90 | TLR8 (0.48) | TLR8TLR7TLR9TLR4IRAK4 | |
| SCHEMBL11890643 | 0.89 | TLR8 (0.44) | TLR8IRAK4HTT | |
| SCHEMBL29082025 | 0.88 | TLR8 (0.48) | TLR8TLR7TLR9TLR4IRAK4 | |
| Trifluoroacetic Acid SCHEMBL25337241 | 0.88 | TLR8 (0.50) | TLR8IRAK4 | |
| SCHEMBL20134852 | 0.82 | TLR8 (0.60) | TLR8TLR7TLR9TLR4IRAK4 | |
| SCHEMBL20135691 | 0.82 | TLR8 (0.57) | TLR8TLR7TLR9TLR4IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117986262-A | Condensed bicyclic compounds, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-116478145-B | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023198114-A1 | ALK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2023-10-19 | — | — | WO | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116478145-A | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | TLR8 1204/4885TLR7 843/4885TLR9 113/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TLR8 2353/4885TLR7 252/4885TLR9 1633/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | TLR8 1209/4885TLR7 795/4885TLR9 104/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | TLR8 4018/4885TLR7 3465/4885TLR9 4245/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TLR8 2353/4885TLR7 252/4885TLR9 1633/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TLR8 2353/4885TLR7 252/4885TLR9 1633/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | TLR8 2684/4885TLR7 2029/4885TLR9 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.